A placebo-controlled clinical trial of tacalcitol for the treatment of vitiligo

Lu-yan TANG,Wen-wen FU,Wen-yu WU,Lei-hong XIANG,Zhi-zhong ZHENG
DOI: https://doi.org/10.3969/j.issn.1000-4963.2005.02.034
2005-01-01
Abstract:Objective: To assess the safety and efficacy of topical tacalcitol for the treatment of vitiligo. Methods: Thirty-four patients with vitiligo were enrolled in a single-blind, auto-controlled clinical trial. Symmetrical or nearby lesions were selected to be treated by either tacalcitol or placebo, and then examined monthly. Results: Thirty patients had been evaluated and the drug was well tolerated. Treatment with tacalcitol result in significantly higher percentage of repigmentation(73.3%),compared with placebo(36.7%). The repigmentation was initiated earlier in the lesions treated with tacalcitol than those with placebo. There was no correlation between the clinical features of vitiligo and the efficacy of tacalcitol. Conclusion: Topical tacalcitol appears to be an effective and well-tolerated drug for vitiligo.
What problem does this paper attempt to address?